Outcome for all patients based on response achieved and type of treatment used. (A) OS probability from onset of HMA treatment in the global cohort. OS probability from onset of HMA treatment according to AML IWG response criteria (for CR/CRi/PD) and MDS IWG response criteria (SD/HI) (B) and according to HMA used (azacitidine vs decitabine) (C).